RCM
ATNM icon

Rotella Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Rotella Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-360
Closed -$29K – 546
2015
Q2 		$29K Buy
+360
New +$30.7K 0.02% 404

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Rotella Capital Management's ATNM Position: Q3 2015 in Review

Rotella Capital Management sold out of Actinium Pharmaceuticals (ATNM) in Q3 2015, closing a stake of 360 shares — an estimated $29K sold.

Rotella Capital Management first reported a position in ATNM in Q2 2015 and held it in 1 quarter. The position peaked at $29K in Q2 2015. 27 funds tracked by Wall St. Rank hold ATNM as of Q3 2015.

  • Rotella Capital Management reported no remaining Actinium Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Rotella Capital Management sold 360 Actinium Pharmaceuticals shares in Q3 2015, an estimated $29K.
  • Rotella Capital Management first reported a position in Actinium Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Rotella Capital Management's Actinium Pharmaceuticals position peaked at $29K in Q2 2015.
  • 27 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2015.

Based on Rotella Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.